Detail akcie Harvard Biosci online

Business Summary: Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Harvard Bioscience Inc revenues decreased 10% to $62.8M. Net loss increased from $12.4M to $53.9M. Revenues reflect Instruments, equipment, software and accessories segment decrease of 12% to $56.6M, China segment decrease of 28% to $7.3M, United States segment decrease of 9% to $28.7M. Higher net loss reflects Other expense, net increase of 59% to $1.3M (expense).